Skip to content

Palvella Therapeutics

US · PVLA #2822 by market cap Listed 1970
130.59 +2.59 +2.02%
Live - 5344 symbols - heartbeat 529s ago · 2026-10-08 04:00
Pre-market 131.00 +0.31%
After-hours 130.70 +0.08%
Overnight 130.05 -0.41%
Market cap
1.88B
P/B
8.68
EPS
-3.71
Reader sentiment Are you bullish or bearish on PVLA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Chardan Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
    Market Newswire · 2026/5/21
  • Rating change
    Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250
    Market Newswire · 2026/6/24
  • Rating change
    Stephens Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $220
    Market Newswire · 2026/5/12
  • Rating change
    Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)
    TipRanks · 2026/7/1
  • Rating change
    LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $267
    Market Newswire · 2026/5/9
  • Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 4.14 Million in Common Stocks
    Market Newswire · 2026/9/12
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA) and MBX Biosciences, Inc. (MBX)
    TipRanks · 2026/5/8
  • Rating change
    H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270
    Market Newswire · 2026/8/6
  • Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240
    Market Newswire · 2026/9/21
  • Rating change
    Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207
    Market Newswire · 2026/8/5
  • BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $210 to $270
    Market Newswire · 2026/5/22
  • Rating change
    A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267
    Market Newswire · 2026/8/5
  • Palvella Therapeutics(PVLA.US) Director Sells US$4.17 Million in Common Stock
    Market Newswire · 2026/9/16
  • Rating change
    CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227
    Market Newswire · 2026/6/25
  • Rating change
    Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210
    Market Newswire · 2026/8/5
  • Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240
    Market Newswire · 2026/9/10
  • Rating change
    Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205
    Market Newswire · 2026/6/22
  • Rating change
    TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267
    Market Newswire · 2026/7/22

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:00:14 · For reference only, not investment advice and not tailored to your situation.